Why uniQure N.V. Stock Is Hopping Today
Shares of the gene therapy company uniQure N.V. (NASDAQ: QURE) rose by as much as 27% in early-morning trading today on over 27 times the average volume. uniQure's stock is responding positively to the unexpected advancement of its experimental hemophilia B treatment, AMT-061, into a late-stage study.
Specifically, uniQure said that it plans to initiate a pivotal-stage trial for AMT-061 in 2018 for patients with severe and moderately severe hemophilia B after consulting with both American and European regulatory authorities on the matter.
Image source: Getty Images.
Source: Fool.com
Uniqure B.V. Stock
€7.68
-5.180%
Based on 1 Buy predictions and 2 Sell predictions the sentiment towards Uniqure B.V. is rather balanced.
However, we have a potential of 43.3% for Uniqure B.V. as the target price of 11 € is above the current price of 7.68 €.
